Developments in AML therapy
LINKS TO ABSTRACTS:
Presentation ID p407-1
Presenter: Jessica Altman, United States
The study authors conclude that their updated analyses show that venetoclax in combination with gilterinib (Ven + Gilt) achieved high rates of mCRc in patients with heavily pretreated and prior TKI-exposed R/R FLT3mut+ AML with encouraging molecular clearance rates. Using similar response criteria to previously studied FLT3mut+ populations, the high mCRc rate with Ven + Gilt reported here suggests strong antileukemic activity. Cytopenias were prominent but manageable. Updated follow-up and molecular data are presented at the meeting.
Presentation ID p407-2
Presenter: Curtis Lachowiez, Houston, United States
The study authors conclude that ivosidenib plus venetoclax plus/minus azacitidine (IVO+VEN +/- AZA) is an effective treatment regimen in patients with IDH1+ myeloid malignancies. The combination therapy is associated with an acceptable and expected toxicity profile with notable efficacy and high rates of MRD-negative CRc in AML.
Presentation ID p407-3
Presenter: Keith Pratz, Philadelphia, United States
The study authors conclude that patients with best response of CRc who achieved MRD<10-3response with venetoclax plus azacitidine treatment had a longer duration of response, overall and event-free survival than patients who were CRc and MRD positive.
Presentation ID p407-4
(S138) EFFECT OF OLUTASIDENIB (FT-2102) ON COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MUTANT IDH1 ACUTE MYELOID LEUKEMIA. RESULTS FROM A PLANNED INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL
Presenter: Stéphane de Botton, Villejuif, France
The study authors conclude that Olutasidenib induced durable complete remissions (CR) in a subset of high-risk R/R mIDH1 AML pts. TI was achieved in all response groups, particularly in those achieving CR. Clinical benefit, as evidenced by duration of response and overall survival, extended to patients who responded but didn’t achieve CR/partial hematologic recovery. A favorable tolerability profile was observed; additional analyses of safety and efficacy are presented.
Presentation ID p407-5
Presenter: Rabia Shahswar, Germany
The study authors conclude that short-term venetoclax can be safely administered in combination with intensive chemotherapy in younger fit adults with AML with tolerable safety-profile, a high ORR rate of 73%, MRD negativity in 47% of responding patients, and promising survival in MRD negative patients.